PMCB News and Press, PharmaCyte Biotech Inc. From 12/14/20

PMCB - PharmaCyte initiates testing of cell therapy in response to FDA recommendations

PharmaCyte Biotech ([[PMCB]] +1.9%) has commenced additional physical parameter testing of its CypCaps encapsulated cells for pancreatic cancer, in line with the recommendations provided by the FDA.The FDA has asked that two additional methods be developed to determine the strength ...

PMCB - PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for its Clinical Trial Product

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has commenced additional physical parameter testing...

PMCB - PharmaCyte Biotech Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the nine-months product ...

PMCB - PharmaCyte Biotech Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has received the clinical hold letter from the U.S....

PMCB - FDA places hold on PharmaCyte's cell therapy IND for pancreatic cancer

OTC listed PharmaCyte Biotech sinks ([[PMCB]] -49.2%) after the FDA placed a hold on the company's Investigational New Drug ((IND)) application for a planned Phase 2b trial in locally advanced, inoperable pancreatic cancer. Details on the reason(s) were not disclosed.PharmaCyte’s ...

PMCB - PharmaCyte Biotech's Investigational New Drug Application Placed on Hold by the U.S. FDA

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has received notification from the U.S. Food and Dr...

PMCB - PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it continues to engage with the U.S. Fo...

PMCB - PharmaCyte Biotech Successfully Completes Six-Month Stability Study

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the six-month produ...

PMCB - PharmaCyte Biotech Successfully Completes Second Container Closure Integrity Test

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the second Containe...

PMCB - PharmaCyte Biotech Announces IND Submitted to U.S. FDA for Clinical Trial in Locally Advanced, Inoperable Pancreatic Cancer

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical-stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has submitted an Investigational New Drug appl...

Company Name:	PharmaCyte Biotech Inc.
Stock Symbol:	PMCB
Market:	OTC
Website:	pharmacyte.com